Vaxart, Inc.
🏢 View company profile →6Patents
6Active
6Granted
47Portfolio score
Filing activity: Feb 28, 2007 → Aug 2, 2022 · 2 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7879602B2 | Chimeric adenoviral vectors | Emerging Cross-Sectional Technologies | 3 | Active |
| US11433146B2 | Formulations for small intestinal delivery of RSV and norovirus antigens | Chemistry; Metallurgy | 1 | Active |
| US8222224B2 | Chimeric adenoviral vectors | Emerging Cross-Sectional Technologies | 1 | Active |
| US8999946B2 | Chimeric adenoviral vectors | Emerging Cross-Sectional Technologies | 0 | Active |
| US9974779B2 | Piperidine derivatives as human papilloma virus inhibitors | Chemistry; Metallurgy | 0 | Active |
| US12186407B2 | Formulations for small intestinal delivery of RSV and norovirus antigens | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.